AMRI to be Acquired by The Carlyle Group
The company will be acquired for $21.75 per share in cash.
On June 6, 2017, AMRI announced that it has signed a definitive agreement to be acquired by affiliates of The Carlyle Group for $21.75 per share in cash. The agreement was unanimously approved by AMRI's Board of Directors, which has recommended that the shareholders vote in favor of the transaction.
Closing of the transaction is subject to customary closing conditions. It is anticipated that the special meeting of AMRI's stockholders to vote on the transaction will be held in the third quarter of 2017, and if the transaction is approved, the merger would be expected to close shortly thereafter.
Source: AMRI
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Drug Solutions Podcast: Gliding Through the Ins and Outs of the Pharma Supply Chain
November 14th 2023In this episode of the Drug Solutions podcast, Jill Murphy, former editor, speaks with Bourji Mourad, partnership director at ThermoSafe, about the supply chain in the pharmaceutical industry, specifically related to packaging, pharma air freight, and the pressure on suppliers with post-COVID-19 changes on delivery.
